NBIX - Neurocrine's Ingrezza meets primary endpoint in late-stage Huntington's trial

Neuorocrine Biosciences' (NASDAQ:NBIX) Ingrezza (valbenazine) met its primary endpoint in a phase 3 trial to treat chorea associated with Huntington's Disease. Shares are up 3% in after-hours trading. Patients in the valbenazine arm achieved a statistically significant mean reduction in the Unified Huntington's Disease Rating Scale Total Maximal Chorea score of 3.2 units between baseline and weeks 10 and 12. Neurocrine plans on submitting an sNDA for Ingrezza in this indicattion next year. Chorea is a movement disorder characterized by involuntary and unpredictable muscle movements. It impacts ~30K adults in the U.S. Read about Neurocrine's recent agreement with Sosei on neuropsychiatric disorders.

For further details see:

Neurocrine's Ingrezza meets primary endpoint in late-stage Huntington's trial